Eagle Pharmaceuticals asserts new patents with trio of lawsuits over cancer drug

Complaints say Slayback, Apotex and Baxter Healthcare infringed two patents through NDAs for leukemia drug injection | Eagle patents issued in last two months expire in 2031.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Eagle Pharma launches new suit over leukaemia drug

6 February 2024 Oncology specialist seeks to block another bendamustine generic following trio of lawsuits in January | Firm filed complaint for patent infringement against Dr Reddy’s.

Americas

Teva and Eagle try to block Bendeka generic

1 July 2021 Teva and Eagle Pharmaceuticals are suing to block a generic version of its leukemia drug Bendeka, arguing its patents still have plenty of time to run.

Americas

Fed Circuit affirms generic maker’s win over Eagle

11 May 2020 The US Court of Appeals for the Federal Circuit has affirmed a generic maker’s victory over pharmaceutical company Eagle Pharmaceuticals in a case involving cancer drug Belrapzo.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Eagle Pharmaceuticals asserts new patents with trio of lawsuits over cancer drug

More on this story

Editor's picks

Editor's picks

More features